SEATTLE, WA - FEBRUARY 12: Medical lab scientists, Glenda Daza (L) and Emily Degli-Angeli (R) work on samples collected in the Novavax phase 3 Covid-19 clinical vaccine trial at the UW Medicine Retrovirology Lab at Harborview Medical Center on February 12, 2021 in Seattle, Washington. The Novavax vaccine requires standard refrigeration temperatures (2 to 8°C) making it easier to store and distribute than those requiring ultra-freezing temperatures. UW Medicine got its first shipment of samples for the clinical trials in January coming from clinics all over the United States and Mexico. (Photo by Karen Ducey/Getty Images)

(AP) – The U.S. is getting another COVID-19 vaccine choice. The Food and Drug Administration on Wednesday cleared Novavax shots for adults. It’s a more traditional type of vaccine than the Pfizer and Moderna shots already used to protect most Americans. Still, millions of adults haven’t yet gotten vaccinated even this late in the pandemic. Experts expect at least some of them to roll up their sleeves for the more conventional technology. The Centers for Disease Control still must recommend how to use the Novavax vaccine before shots begin. The U.S. has bought 3.2 million doses.